Perioperative treatment with human recombinant interferon-gamma: A randomized double-blind clinical trial

Shock

Volumn 16, Issue 5, 2001, Pages 329-333

  Schinkel, Christian ^a   Licht, Katharina ^a   Zedler, Siegfried ^a   Schinkel, Svenja ^a   Fuchs, Dietmar ^b   Faist, Eugen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Clinical study; IFN ; Monocytes; Proinflammatory cytokines

Indexed keywords

CD14 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ANTIGEN; LIPOPOLYSACCHARIDE; RECOMBINANT GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN TEST; SURGERY;

ANTIGENS, CD; ANTIGENS, CD14; DOUBLE-BLIND METHOD; FEMALE; HLA-DR ANTIGENS; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOPHENOTYPING; INTERFERON-GAMMA, RECOMBINANT; INTERLEUKIN-1; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PILOT PROJECTS; SKIN TESTS; SURGICAL PROCEDURES, OPERATIVE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035513447     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-200116050-00001     Document Type: Article

References (42)

1. De Maeyer E, De Maeyer-Guignard J: Interferon effects on cellular and humoral immunity. In Baron S, (ed): The interferon system: A current review. Austin, TX: University of Texas Press, pp 327-335, 1987.
2. Nathan CF, Mirray HW, Wiebe ME, Rubin BY: Identification of interferon-γ as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 158:670-689, 1983.
3. Ishizuka T, Hirata I, Adachi M, et al.: Effects of interferon-gamma on cell differentiation and cytokine production of a human monoblast cell line, U 937. Inflammation 19:627-636, 1995.
4. Livingston DH, Appel SH, Wellhausen SR, et al.: Depressed interferon gamma production and monocyte HLA-DR expression after severe injury. Arch Surg 123:1309-1312, 1988.
5. Faist E, Mewes A, Strasser T, et al.: Alteration of monocyte function following major trauma. Arch Surg 123:287-292, 1988.
6. Hershman MJ, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC: Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clin Exp Immunol 77:67-70, 1989.
7. Dries DJ, Jurkovich GJ, Maier RV, et al.: Effect of interferon-gamma on infection related death in patients with severe injuries. Arch Surg 129:1031-1041, 1994.
8. Polk HC, Cheadle WG, Livingston DA, et al.: A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am J Surg 163:191-196, 1992.
9. Ertel W, Morrison MH, Ayala A, Dean RE, Chaudry IH: Interferon-γ attenuates hemorrhage-induced suppression of macrophage and splenocyte functions and decreases susceptibility to sepsis. Surgery 111:177-187, 1992.
10. Doherty GM, Lange JR, Langstein HN, Alexander HR, Buresh CM, Norton JA: Evidence for IFN-γ as a mediator of the lethality of endotoxin and tumor necrosis factor-α. J Immunol 149:1666-1670, 1992.
11. Jurkovich GJ, Mileski WJ, Maier RV, Winn RK, Rice CL: Interferon-α increases sensitivity to endotoxin. J Surg Res 51:197-203, 1991.
12. Redmond HP, Chavin KD, Bromberg JS, Daly JM: Inhibition of macrophage-activating cytokines is beneficial in the acute septic response. Ann Surg 214: 502-509, 1991.
13. Jones HJS, de Cossart L: Risk scoring in surgical patients. Br J Surg 86:149-157, 1999.
14. Ertel W, Kremer JP, Kenney J, et al.: Down-regulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85:1341-1347, 1995.
15. Kenney JS, Masada MP, Eugui EM, Delustro BM, Mulkins MA, Allison AC: Monoclonal antibodies to human recombinant Interleukin 1 (IL 1) beta: Quantitation of IL 1 beta and inhibition of biological activity. J Immunol 138:4236-4242, 1987.
16. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor TNF from human monocytes. J Immunol Methods 95:99-105, 1986.
17. Mosmann T: Rapid colorometric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Methods 65:55-63, 1983.
18. Faist E, Storck M, Hueltner L, et al.: Functional analysis of monocyte activity through synthesis patterns of proinflammatory cytokines and neopterin in patients in surgical intensive care. Surgery 112:562-572, 1992.
19. The International Chronic Granulomatous Disease Cooperative Study Group: A controlled trial of interferon-gamma to prevent infection in chronic granulomatous disease. N Engl J Med 324:509-516, 1991.
20. Badaro R, Falcoff E, Badaro FS, et al.: Treatment of visceral leishmaniasis with pentavalent antimony and interferon-gamma. N Engl J Med 322:16-21, 1990.
21. Wasserman D, Ioannovich JD, Hinzmann RD, et al.: Interferon-γ in the prevention of severe burn-related infections: A European phase III multicenter trial. Crit Care Med 26:434-439, 1998.
22. Doecke WD, Randow F, Syrbe U, et al.: Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med 3:678-681, 1997.
23. Schinkel C, Licht K, Zedler S, et al: Interferon gamma (IFN-γ) modifies cytokine release in vitro by monocytes from surgical patients. J Trauma (in press).
24. Pietsch JB, Meakins JL, MacLean LD: The delayed hypersensitivity response: application in clinical surgery. Surgery 82:349-355, 1977.
25. Hershman MJ, Cheadle WG, Appel SH, et al.: Comparison of antibody response with delayed hypersensitivity in severely injured patients. Arch Surg 124:339-341, 1989.
26. Christou NV: Host-defense mechanisms in surgical patients: a correlative study of delayed type hypersensitivity, skin test response, granulocyte function and sepsis in 2,202 patients. Can J Surg 28:39-45, 1985.
27. Faist E, Storck M, Stettner A, Ertel W, Ax W, Schildberg FW: Correlation of in vitro and in vivo CMI parameters to identify patients at risk undergoing elective operative trauma. Langenbecks Archiv Chir 90(suppl):181-186, 1990.
28. Cheadle WG, Mercer-Jones M, Heinzelmann M, Polk HC Jr: Sepsis and septic complications in the surgical patient: who is at risk? Shock 6(suppl.1):6-9, 1996.
29. Christou NV, Meakins JL, Gordon J, et al.: The delayed hypersensitivity response and host resistance in surgical patients: twenty years later. Ann Surg 222:534-546, 1995.
30. Fuchs D, Hausen A, Reibnegger, et al.: Neopterin as a marker for activated cell-mediated immunity. Immunol Today 9:150-154, 1988.
31. Browning JL, Ribolini A: Interferon blocks interleukin 1-induced prostaglandin release from human peripheral monocytes. J Immunol 138:2857-2863, 1987.
32. Ertel W, Keel M, Neidhardt R, et al.: Inhibition of the defense system stimulating interleukin-12 interferon-γ pathway during critical illness. Blood 89: 1612-1620, 1997.
33. Heremans H, Van Damme J, Dillen C, Dijkmans R, Billiau A: Interferon-γ, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock reactions in mice. J Exp Med 171:1853-1869, 1990.
34. Kiener P, Marek F, Rodgers G, Lin P, Warr G, Desiderio J: Induction of tumor necrosis factor, IFN-γ and acute lethality in mice by toxic and non-toxic forms of lipid A. J Immunol 141:870-874, 1988.
35. Mock CN, Dries DJ, Jurkovich GJ, Maier RV: Assessment of two clinical trials: interferon-gamma therapy in severe injury. Shock 5:235-240, 1996.
36. Langdale LA, Wilson L, Jurkovic GJ, Liggitt HD: Effects of immunomodulation with interferon-γ on hepatic ischemia-reperfusion injury. Shock 11:356-361, 1999.
37. Maluish AE, Urba WJ, Longo DL, et al.: The determination of an immunologically active dose of interferon-gamma in patients with melanoma. J Clin Oncol 6:434-445, 1988.
38. Al Kharfy KM, Kellum JA, Matzke GR: Unintended immunomodulation: Part II. Effects of pharmacological agents on cytokine activity. Shock 13:346-360, 2000.
39. Murray HW: Interferon-gamma and host antimicrobial defense: current and future clinical applications. Am J Med 97:459-467, 1994.
40. Schinkel C, Sendtner R, Zimmer S, Walz A, Hueltner L, Faist E: Evaluation of Fc-receptor positive and negative monocyte subsets in sepsis. Shock 11:229-234, 1999.
41. Zedler S, Bone RC, Baue AE, von Donnersmarck GH, Faist E: T-cell reactivity and its predictive role in immunosuppression after burns. Crit Care Med 27: 66-72, 1999.
42. Cartwright N, Demaine A, Jahromi M, Sanders H, Kaminski ER: A study of cytokine protein secretion, frequencies of cytokine expressing cells and IFN-γ gene polymorphisms in normal individuals. Transplantation 68:1546-1552, 1999.